1-9 of 9
fenretinide
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase 1a/1b Trial of ST-001, a Fenretinide Phospholipid Suspension for 4-Hour Intravenous Infusion in Relapsed/Refractory T-Cell Non-Hodgkin's Lymphoma

Ayad Al-Katib, MD, Timothy M. Kuzel, MD, Ralph Parchment, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4041.
https://doi.org/10.1182/blood-2019-127278
Published: 2019
Journal Articles

The Crucial Role of NR4A1 Dependent Apoptosis Induced By Fenretinide in Acute Myeloid Leukemia

Jie Xiong, Xingyi Kuang, Tingting Lu, Bingqing Cheng, Danna Wei, Xinyao Li, Weili Wang, Zhaoyuan Zhang, Jishi Wang, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 5266.
https://doi.org/10.1182/blood-2018-99-117776
Published: 2018
Journal Articles

Chemosensitizing Effect of Fenretinide-Induced NF-κb Inhibition in AML Therapy

Ranran Zhang, MD, Wei Fenggui, MD, Ru Chen, MD, Ming Liang, MD, Liping Wu, MD, Hui Zhang, MD, PhD, Fuxiong Chen, MD
Journal: Blood
Blood (2016) 128 (22): 1580.
https://doi.org/10.1182/blood.V128.22.1580.1580
Published: 2016
Journal Articles

Results of a Phase I-II Study of Fenretinide and Rituximab for Patients with B-Cell Lymphomas

Andrew J. Cowan, MD, Philip Stevenson, M.S., Ted A. Gooley, PhD, Shani L. Frayo, George R. Oliveira, MD, Stephen D. Smith, MD, Damian J. Green, MD, Jennifer E. Roden, John M. Pagel, MD PhD, Brent L Wood, MD PhD, Oliver W Press, MD PhD, Ajay K. Gopal, MD
Journal: Blood
Blood (2015) 126 (23): 2728.
https://doi.org/10.1182/blood.V126.23.2728.2728
Published: 2015
Journal Articles

Coordination of Fenretinide-Induced Apoptosis by Stress-Responsive Regulators in Leukemia Cells

Kankan Wang, Hai Fang, Da-Kai Xiao, Xue-Hua Zhu, Miao- Miao He, Xiao-Ling Pan, Sai-Juan Chen, PhD, Ji Zhang
Journal: Blood
Blood (2008) 112 (11): 4730.
https://doi.org/10.1182/blood.V112.11.4730.4730
Published: 2008
Journal Articles

Phase I Trial of Fenretinide (4-HPR) Intravenous Emulsion for Hematologic Malignancies.

Ann Mohrbacher, MD, Martin Gutierrez, MD, Anthony J. Murgo, MD, Shivaani Kummar, MD, C. Patrick Reynolds, MD, PhD, Barry J. Maurer, MD, PhD, Susan Groshen, PhD, Lori Vergara, RN, Min H. Kang, Pharm D, Allen S. Yang, MD, PhD
Journal: Blood
Blood (2007) 110 (11): 2581.
https://doi.org/10.1182/blood.V110.11.2581.2581
Published: 2007
Journal Articles

Fenretinide (4HPR) Inhibits Growth of Myeloma Cells in Their Microenvironment and Is a Potent Inhibitor of Angiogenesis and Osteoclastogenesis.

Xin Li, PhD, Wen Ling, Rinku Saha, Paul Perkins, Angela Pennisi, Shmuel Yaccoby, Ph.D.
Journal: Blood
Blood (2006) 108 (11): 3480.
https://doi.org/10.1182/blood.V108.11.3480.3480
Published: 2006
Journal Articles

Apoptotic Cross-Talk between Organelles Induced by Fenretinide in Hematopoietic Malignancy.

Kankan Wang, MD, PhD, Dakai Xiao, Ph.D., Yanzhi Du, Ph.D, Huiyong Fan, B.Sci, Yulong Chen, B.Sci, Saijuan Chen, MD, Ph.D, Zhu Chen, MD, Ph.D, Ji Zhang, Ph. D.
Journal: Blood
Blood (2005) 106 (11): 4430.
https://doi.org/10.1182/blood.V106.11.4430.4430
Published: 2005
Journal Articles

Fenretinide enhances rituximab-induced cytotoxicity against B-cell lymphoma xenografts through a caspase-dependent mechanism

Ajay K. Gopal, John M. Pagel, Nathan Hedin, Oliver W. Press
Journal: Blood
Blood (2004) 103 (9): 3516–3520.
https://doi.org/10.1182/blood-2003-08-2795
Published: 2004